Clinical Research on Accuray's CyberKnife? and TomoTherapy? Systems to Be
Presented at Key Industry Event for Medical Physicists
Accuray to Host an Educational Symposium Highlighting Enhanced Capabilities of
Its CyberKnife and TomoTherapy Treatment Systems
SUNNYVALE, Calif., July 29, 2012 /PRNewswire via COMTEX/ -- Accuray Incorporated
(ARAY), the premier radiation oncology company, announced today that more than 70
studies on the clinical use of the CyberKnife Robotic Radiosurgery? System and
the TomoTherapy? System will be presented at the 54th Annual Meeting of the
American Association of Physicists in Medicine (AAPM) taking place in Charlotte,
N.C. July 29 - August 2, 2012. The Annual AAPM Meeting usually draws about 4,000
attendees.
Studies from leading centers will showcase both the CyberKnife System and the
TomoTherapy System. The presentations continue to validate Accuray's
standard-setting treatment planning and delivery techniques, accurate patient
setup and intrafraction motion tracking, as well as quality assurance practices
for the industry's premier, fully-integrated radiosurgery and intensity-modulated
radiotherapy platforms. Of note are studies that emphasize the benefits of each
technology in demanding clinical situations. Key examples are the TomoTherapy
System's unmatched ability to provide organ sparing and dose homogeneity in
hippocampal-avoidance whole brain radiotherapy and the CyberKnife System's
ability to maintain continual tracking accuracy during treatment of liver tumors
undergoing a large degree of respiratory motion.
Accuray will also host a symposium on Monday, July 30, 2012 from 12:30 p.m. EDT -
1:30 p.m. EDT at The Westin Charlotte Hotel. The session will focus on Accuray's
new VoLO(TM) technology for the TomoTherapy System, a treatment planning platform
that leverages advanced parallel processing technology and a new dose calculation
algorithm to increase clinical efficiency, throughput and flexibility in
developing even the most complex treatment plans. In addition, the symposium will
highlight TomoTherapy's new Dose Control System, improving system stability
during and between treatments.
"Medical physicists play a vital role in the radiation therapy field, ensuring
patient safety and treatment quality, two areas to which Accuray is strongly
dedicated," said Euan S. Thomson, Ph.D., Accuray president and chief executive
officer."We are pleased by the quantity and quality of clinical research being
presented. This work adds to the growing body of scientific evidence validating
the safe and effective use of our products for an expanding range of clinical
indications."
Accuray will be exhibiting at booth #909. Presenters include Robert Staton,
Medical Physicist, MD Anderson Orlando who will be presenting on his experience
with the TomoTherapy Dose Control System and Kenneth Ruchala, Ph.D., Accuray
Incorporated who will be presenting information on the Non-Voxel Broad Beam
algorithm for a GPU-based dose calculator. Additionally, Accuray will host
demonstrations of its VoLO technology for the TomoTherapy System at the booth.
The TomoTherapy System is a fully integrated 3D image guided intensity modulated
radiation therapy system that provides patients with the most accurate,
personalized cancer care. The technology uses daily computed tomography (CT)
imaging to identify the exact position of the tumor on each day of treatment,
enabling clinicians to customize treatment for each patient, minimize radiation
exposure to healthy tissue and reduce side effects. The TomoTherapy System uses a
radiation beam that continually rotates in 360 degree arcs about the patient,
meaning that treatments can be delivered continuously to the tumor from every
angle.
The CyberKnife System is the first and only robotic radiosurgery system that
provides a pain-free, non-invasive treatment option for patients who are looking
for an alternative to surgery or who have an inoperable or surgically complex
tumor. CyberKnife treatment is typically completed in just one to five days,
instead of the 40 or more treatment sessions typically required with conventional
radiation therapy. The CyberKnife System offers unique capabilities that
automatically account for the natural motion of the tumor throughout treatment.
The ability to manage motion in real time helps ensure that radiation is
delivered only to the tumor while sparing healthy tissue and critical structures.
About AccurayAccuray Incorporated (ARAY), based in Sunnyvale, Calif., is the
premier radiation oncology company that develops, manufactures and sells
personalized innovative treatment solutions that set the standard of care, with
the aim of helping patients live longer, better lives. The Company's leading edge
technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver
radiosurgery, stereotactic body radiation therapy, intensity modulated radiation
therapy, image guided radiation therapy, and adaptive radiation therapy. To date
635 systems have been installed in leading hospitals around the world. For more
information, please visit accuray.com.
Safe Harbor Statement Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release relate, but are not
limited, to reduced radiation exposure, accuracy, clinical efficiency, clinical
applications, and clinical benefits. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially from
expectations, including risks detailed from time to time under the heading "Risk
Factors" in the Company's report on Form 10-K for fiscal year 2011, and its
reports on Form 10-Q for the first, second and third quarters of fiscal 2012.
Forward-looking statements speak only as of the date the statements are made and
are based on information available to the Company at the time those statements
are made and/or management's good faith belief as of that time with respect to
future events. The Company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in assumptions or
changes in other factors affecting forward-looking information, except to the
extent required by applicable securities laws. Accordingly, investors should not
place undue reliance on any forward-looking statements. |
